New study calls for hepatitis C to be considered a cardiovascular risk factor
April 23, 2015, Vienna, Austria: Results from a new study demonstrate that chronic hepatitis C virus (HCV) infection is associated with a higher risk of developing cardiovascular diseases and significantly increases cost of care and length of time in hospital. Based on these results, revealed today at The International Liver CongressTM 2015, study investigators conclude that chronic HCV infection should be considered a risk factor for the development of cardiovascular diseases.
In the study, inpatient prevalence of diagnosed HCV infection was 1.9%. For these patients, the adjusted odds ratio (OR) for acute myocardial infarction was 2.29 (CI: 2.22−2.36); for coronary artery disease: 1.88 (CI: 1.83−1.93); for cerebrovascular accident: 1.98 (CI: 1.93−2.04) and for congestive heart failure: 1.08 (CI: 1.06–1.10).
In this study, patients with HCV infections were characterised using the weighted 2011 Nationwide Inpatient Sample (NIS) data.
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.
About EASL (www.easl.eu)
Since EASL’s foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
For more information, please contact the ILC Press Office at:
• firstname.lastname@example.org or
• +44 (0)20 3580 5444